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Paediatric research has resulted in improvements in child health and outcomes of healthcare. Moreover, improving the health and wellbeing has far reaching implications for adult health and reducing the growing burden of non-communicable, chronic adult diseases. This Comment outlines how the future of paediatric research in Europe can be optimized by generalizing current good practice across Europe.  A vibrant research environment requires funding and a number of other factors. Crucial to success are the involvement of paediatricians and other child health professionals, the support and engagement of children, young people, and their families, infrastructure that promotes collaboration, a regulatory framework that recognises the needs of infants, children, and young people, and a cadre of child health academic leaders (1,2).
In Europe the major paediatric societies espouse research as a core doctrine. However, to date their activities have generally been limited to disseminating research through conferences and a very limited role in research funding.  The central importance of research about children to the future of Europe has been recognized in the 2016 Road Map of the European Strategic Forum of Research Infrastructure. The Road Map includes the European Paediatric Clinical Trials Research Infrastructure (ECPTRI) which is  collaborating with the European Clinical Research Infrastructure Network (ECRIN) to develop systems for the management of multinational clinical trials for children. This work has been awarded €3.3 million to help trials that have been awarded funding to open in multiple countries. Through the CORBEL project EPCTRI will link the child health community to a number of other research infrastructures including pre-clinical (animal) expertise, biomarkers and imaging.
Innnovative Medicines initiative (IMI) 2 (https://www.imi.europa.eu/content/imi-2 (​https:​/​​/​www.imi.europa.eu​/​content​/​imi-2​)) will launch a call for a paediatric clinical trials network in collaboration with industry. This will match, and share operating principles, with a similar network in the US: the Institute for Advanced Clinical Trials for Children (iACT for Children). [3] The European Commission has funded a significant amount of paediatric research. For example, 19 projects were funded under European Union (EU) 7 th Framework Programme for Research and Technological Development (FP7) to support research into off-patent medicines [4]. However, Horizon 2020 (H2020), The EU Framework Programme for Research and Innovation and other major funders require combined lobbying from a paediatric research alliance including all paediatric/child health societies and stakeholders to ensure children research is adequately funded. For example, the Royal College of Paediatric and Child Health, UK (RCPCH) has led the establishment of a UK Child Health Research Collaboration, providing a forum for children’s research charities to come together to fund, advocate, or lobby. This and similar work by the paediatric oncology community needs to be generalized across all European countries, therapeutic areas and paediatric age groups. There are commonalities across the paediatric age groups that facilitate the development of a vibrant research community. The RICHE project is a response to a call to clearly identify gaps in European child health research, and to provide justified guidance on priorities for investments in research over the next decade [5].
Participatory research including parent and family groups in all areas of the research from inception to result publication is evolving and will increase the visibility and lobbying potential for Paediatric Research as exemplified in the RCPCH Children’s Research Charter. The European Network of Young People’s Advisory Groups has developed ways to present the voices of children and young people to other stakeholders at all stages of research. A number of countries have developed, or are developing, framework and infrastructural support for children’s research. These are shown in Figure 1. Recent advances on collaborative paediatric medicine for children such as the Global Research in Paediatrics – Network of Excellence (GRiP), have stimulated and facilitated the development and safe use of medicines in children (http://www.grip-network.org/index.php/cms/en/Home). The development of common standards and regulatory approaches is an urgent requirement. The International Neonatal Consortium is an exemplar of this [6,7]. In addition, Global funding Bill and Melinda Gates has dramatically increased funding to children especially to neonates and this success may be a template for more private sponsoring of pediatric research.
Education and training about research is essential for the future development of child health. A number of initiatives have been developed. For example, the GRiP has developed an International Masters Degree in Paediatric Drug Development and Evaluation together with a one – two day roadshow about the study of medicines in children.   The RCPCH is introducing training in generic research competencies into training for all paediatricians (8).  
	The future of paediatric research depends on concerted action to develop research infrastructure and true engagement with children, young people and families. This needs support from policymakers (who need to be lobbied), educators and the broad child health community. Then, the creativity and energy of child health professionals will be harnessed effectively to the needs of babies, children and young people.
Action points 
	Develop a pan-European forum for discussion among learned societies and other groups about priorities and key messages
	Lobby European Commission and national governments about the priorities and key messages
	Respond to the consultation on the 10 year review of the Paediatric Regulation to ensure that children’s needs continue to be met
	Focus on medicines research as an easy to justify activity but generalize lessons learnt to other aspects of child health
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